Choose Injection Sites With Adequate Subcutaneous Tissue Injection sites with minimal subcutaneous fat, such as the inner thigh, the lower abdomen in leaner individuals, or areas close to bony prominences, offer less tissue cushioning between the needle and sensory nerve endings
Clear solution
10.1016/j.aninu.2015.08.008 80
Originally developed to treat obesity, AOD-9604 has since gained traction in the functional medicine community as a powerful tool for improving body composition and metabolic flexibility
0.22 m) prior to use Aliquot and store reconstituted solutions at 20 C or below to minimise degradation Avoid repeated freezethaw cycles Precautions & Notes Experimental behaviour of BPC-157 is dependent on concentration, model system, and exposure conditions Due to reported interaction with multiple signalling pathways, appropriate experimental controls are recommended Prolonged exposure to light, elevated temperature, or aqueous environments may reduce stability As of 2022, BPC-157 (PL-14736) is listed by the World Anti-Doping Agency (WADA) under the S0 category of prohibited substances
This leaves the nerve stuck in a state of dysfunction, constantly misfiring pain signals or failing to transmit touch sensations
